Paul Aisen, MD

Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.

• The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study
  NIH · R01AG095009 · Sep 1, 2025 – Aug 31, 2030 · Role: Co-Principal Investigator
• Life?s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study
  NIH · R01AG095004 · Aug 15, 2025 – Jul 31, 2028 · Role: Co-Principal Investigator
• Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months
  NIH · R01AG065248 · Jun 1, 2020 – May 31, 2027 · Role: Co-Principal Investigator
• Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
  NIH · R01AG063689 · May 15, 2019 – Dec 31, 2024 · Role: Co-Principal Investigator
• Combination anti-amyloid therapy for preclinical Alzheimer's disease
  NIH · R01AG061848 · Sep 30, 2018 – May 31, 2025 · Role: Principal Investigator
• API A4 Alzheimer's Prevention Trial
  NIH · R01AG058468 · Sep 1, 2018 – Nov 30, 2025 · Role: Co-Principal Investigator
• Alzheimer's Clinical Trials Consortium (ACTC)
  NIH · U24AG057437 · Dec 2, 2017 – Aug 31, 2028 · Role: Principal Investigator
• Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease
  NIH · R01AG053798 · May 1, 2017 – Apr 30, 2024 · Role: Principal Investigator
• The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease
  NIH · R01AG054029 · Aug 15, 2016 – Apr 30, 2024 · Role: Co-Principal Investigator
• Long-Term Nicotine Treatment of Mild Cognitive Impairment
  NIH · R01AG047992 · Sep 15, 2015 – May 31, 2022 · Role: Co-Principal Investigator
• A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
  NIH · R01AG030048 · Aug 1, 2008 – Jun 30, 2015 · Role: Principal Investigator
• Pilot Study of Huperzine A in Alzheimer's Disease
  NIH · R01AG019268 · Sep 30, 2001 – Aug 31, 2007 · Role: Principal Investigator
• Alzheimer's Disease Cooperative Study
  NIH · U19AG010483 · Jul 1, 1997 – Feb 28, 2021 · Role: Co-Principal Investigator
• Alzheimer's Disease Cooperative Study (ADCS)
  NIH · U01AG010483 · Sep 30, 1991 – Nov 30, 2012 · Role: Principal Investigator

• Thompson, Paul
• Schneider, Lon
• Toga, Arthur
• Rissman, Robert
• Ringman, John
• Raman, Rema